Simon Partridge joined Sheffield Hallam University in 2017 and is a research associate. He is currently working on an Arthritis Research UK (ARUK) to help develop, characterise and commercialise a patented synthetic thermosensitive injectable hydrogel for the treatment of degenerative disc disease.
Simon's PhD was studying the influence of hydroxyapatite nanoparticle synthesis and polymer nanocomposites on patient derived human mesenchymal stem cells. He has a biomedical science background with expertise in stem cell biology, biomaterials, medical devices and tissue engineered constructs.
Simon's core responsibilities as a post-doctoral researcher are to ensure that key objectives from the funded projects are met, support of other members from the groups, publication of scientific reports and dissemination of information to scientific and pubic platforms. He is also a member of the British Orthopedic Research Society.
Simon is currently undertaking in depth materials testing of the hydrogel to provide the foundation for the investigational medicinal product dossier (IMPD), which is essential for the translation the material into the clinic.
Simon is interested the development of new biomaterials that can orchestrate tissue regeneration and match the biomechanics of the implant site.
He also has a keen interest in utilising biomaterials to treat diseases, but also as scaffolds to construct 3D tissues ex vivo or drug discovery and disease modelling.
- Polymers, Nanocomposites and Modelling Research Centre
- Materials and Engineering Research Institute
2017 - Present: Sniper - Surgical Nanoformulations of Injectable Poly nipam for Effective Regeneration of the Intervertebral Disc.
2016 - 2017: Newcastle University, UK NC3R’s CRACK-IT phase I, Development of an in-vitro model to recapitulate the human osteoarthritic joint.
2014 - 2016: Newcastle University, UK EPSRC funded Medical Device Innovation (MeDe). Minimally invasive implantation of bioactive materials – Development of materials and surgical processes to produce novel complex implants in-vivo.